Viridian Therapeutics, Inc. (VRDN)
13.31
-0.17
(-1.26%)
USD |
NASDAQ |
May 01, 14:37
Viridian Therapeutics Enterprise Value : 685.84M for April 30, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 232.96B |
| Marker Therapeutics, Inc. | 7.300M |
| Boston Scientific Corp. | 95.78B |
| Plus Therapeutics, Inc. | 29.84M |
| Nutriband, Inc. | 42.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -101.98M |
| Revenue (Quarterly) | 0.132M |
| Total Expenses (Quarterly) | 102.11M |
| EPS Diluted (Quarterly) | -1.080 |
| Gross Profit Margin (Quarterly) | -142.4% |
| Profit Margin (Quarterly) | -77.26K% |
| Earnings Yield | -28.60% |
| Normalized Earnings Yield | -28.56 |